The differential expression of ZNF419 between tumor and normal samples was analyzed (Supplementary Figure 1) and we found that ZNF419 was significantly expressed in most cancers, including PRAD, stomach and esophageal carcinoma (STES), KIRC, LUSC, LIHC, and BLCA. Here, ZNF419 is linked to digestive system neoplasm.